FDA Shuffles Animal Meds List for Clarity
Published Date: 5/9/2025
Rule
Summary
The FDA is updating rules about new animal medicines based on recent approvals and changes from early 2025. These updates affect drug makers and pet owners by making the rules clearer and reflecting the latest drug approvals and withdrawals. This means safer, better-regulated animal medicines are on the way, with no surprise costs or delays.
Analyzed Economic Effects
2 provisions identified: 2 benefits, 0 costs, 0 mixed.
Regulations Updated for Jan–Mar 2025 Approvals
The FDA amended animal drug rules to reflect application-related actions for new animal drug applications (NADAs), abbreviated NADAs (ANADAs), and conditionally approved NADAs (CNADAs) that occurred during January, February, and March 2025. This change records recent approvals, withdrawals, and sponsor changes from that three-month period.
Rules Clarified to Improve Safety and Clarity
The FDA amended animal drug regulations to improve their accuracy and readability, which the agency says will make rules clearer for drug makers and pet owners and support safer, better-regulated animal medicines without surprise costs or delays. The amendments are described as improving accuracy and readability of the regulations.
Personalized for You
How does this regulation affect your finances?
Personalize government policy and PRIA will tell you what this federal register document means for your household, plus every other regulation we track. PRIA reads each provision against your financial profile to show you exactly what matters to your wallet.
Key Dates
Department and Agencies
Related Federal Register Documents
2026-16296, Substances Generally Recognized as Safe
The Food and Drug Administration (FDA or we) is proposing to require the submission of generally recognized as safe (GRAS) notices for the use of a human or animal food substance purported to be GRAS under the conditions of its intended use under the Federal Food, Drug, and Cosmetic Act (FD&C Act).
2026-14073, Drug Establishment Registration and Drug Listing Requirements for Establishments Engaged in Distributed Manufacturing and Certain Foreign Establishments
The FDA wants to make it easier for drug makers who work in several locations to register as one company instead of many. They’re also updating rules for foreign drug companies to match new laws about handling health threats. If you’re in drug manufacturing, get ready to comment by September 11, 2026, and keep an eye on possible paperwork changes that could affect your business.
2026-13047, Establishment Registration and Product Listing for Tobacco Products
The FDA wants to make sure all tobacco product makers, both in the U.S. and abroad, register their businesses and list their products. This new rule closes a big gap by including foreign companies, helping the FDA keep better track of tobacco products for public health. Comments on this proposal are open until September 14, 2026, so affected businesses should get ready to update their info and possibly face new costs.
2026-16714, Agency Information Collection Activities; Proposed Collection; Comment Request; Third Party Disclosure and Recordkeeping Requirements for Reportable Food
The Food and Drug Administration (FDA or the Agency) is announcing an opportunity for public comment on the proposed collection of certain information by the Agency. Under the Paperwork Reduction Act of 1995 (PRA), Federal Agencies are required to publish notice in the Federal Register concerning each proposed collection of information, including each proposed extension of an existing collection of information, and to allow 60 days for public comment in response to the notice. This notice solicits comments on the information collection provisions of FDA's third-party disclosure and recordkeeping requirements for reportable food.
2026-16712, Agency Information Collection Activities; Proposed Collection; Comment Request; Imports and Electronic Import Entries
The FDA wants your thoughts on how they collect info about imports and electronic import entries. If you’re involved in importing goods, this could affect you! They’re asking for comments by October 16, 2026, to help improve the process without adding extra costs or hassle.
2026-16715, Agency Information Collection Activities; Proposed Collection; Comment Request; Investigational New Drug Application Requirements
The Food and Drug Administration (FDA) is announcing that a proposed collection of information has been submitted to the Office of Management and Budget (OMB) for review and clearance under the Paperwork Reduction Act of 1995.
Previous / Next Documents
Previous: 2025-08129, Federal Management Regulation; Nondiscrimination Clarification in the Federal Workplace; Rescission
The government is canceling a rule that explained how to stop sex discrimination at work. This change affects all federal employees and is based on a new order focused on protecting traditional views about gender. No new costs or deadlines are involved, but federal workplaces will follow updated guidance soon.
Next: 2025-08143, Medical Devices; Immunology and Microbiology Devices; Classification of the DNA-Based Test To Measure Minimal Residual Disease in Hematological Malignancies
The FDA is officially putting the DNA test that checks for tiny amounts of blood cancer back into a safer, more controlled category called Class II. This means the test will have special rules to make sure it works well and is safe, helping patients get better access to this cool technology faster. Companies making these tests should get ready for these new rules, which aim to keep things safe without slowing down innovation.